Peter Richardson
About Peter Richardson
Peter Richardson is the VP of Pharmacology at BenevolentAI and Director at HELIONS CONSULTING LIMITED, with extensive experience in the biotechnology sector and a strong academic background in biochemistry.
Current Role at BenevolentAI
Peter Richardson is the Vice President of Pharmacology at BenevolentAI. Based in Cambridge, UK, he has been with the company since September 2018. As VP of Pharmacology, Peter is involved in leveraging artificial intelligence technology to advance drug discovery processes. One notable project includes his work on identifying potential treatments for COVID-19 using AI methodologies.
Director at HELIONS CONSULTING LIMITED
In addition to his role at BenevolentAI, Peter Richardson serves as Director at HELIONS CONSULTING LIMITED. This role allows him to apply his extensive experience in pharmacology and biotechnology to provide strategic consulting services. His expertise supports various clients in navigating complex scientific and regulatory landscapes.
Leadership Experience at GrantaBio LLP
Peter Richardson was the Director at GrantaBio LLP from 2009 to 2013. During his four-year tenure in Cambridge, England, he oversaw significant developments in biotechnology projects. His role as Director involved strategic decision-making and guiding the company through various phases of scientific innovation and commercialization.
Head of Discovery at Biovitrum AB (publ)
From 2005 to 2009, Peter Richardson worked as the Head of Discovery at Biovitrum AB (publ) in Cambridge, England. In this role, he was responsible for leading early-stage research and development efforts. His tenure contributed to the discovery and initial development of several promising therapeutic candidates.
Academic Background and Education
Peter Richardson has a solid academic foundation in biochemistry. He earned a Doctor of Philosophy (PhD) from the University of Cambridge from 1976 to 1979. Before that, he completed a Master of Arts (MA) in Biochemistry at the University of Oxford from 1972 to 1976. His academic background laid the groundwork for a distinguished career in pharmacology and biotechnology.
Industry Contributions and AI Drug Discovery
Peter Richardson has significantly contributed to the biotechnology industry over the past three decades. His work has spanned roles in academia and industry, including his participation in the AI Drug Discovery Summit. One of his notable contributions includes using AI to identify potential COVID-19 treatments, showcasing his ability to integrate cutting-edge technology into pharmaceutical research.
Senior Lecturer at University of Cambridge
Peter Richardson served as a Senior Lecturer at the University of Cambridge from 1989 to 2006. During his 17-year tenure, he educated and mentored many students in biochemistry and pharmacology. His role included conducting research, delivering lectures, and contributing to the academic community's understanding of biochemical processes.